Combination immunotherapy for men with mCRPC: another new trial proposed

Late yesterday, Advaxis Immunotherapies announced the potential initiation of human trials of another new form of immunotherapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …